Featured Research

from universities, journals, and other organizations

New insight into how 'chemical switch' that increases risk of stroke and heart disease risk is turned on

Date:
March 6, 2012
Source:
University of Leicester
Summary:
Scientists investigating a ‘biochemical switch’ linked to strokes and heart disease claim to have made an advance in understanding how it is ‘turned on’.

Model of the human P2X1 receptor for ATP, the three subunits that make up the functional receptor are shown in red, white and blue.
Credit: Image courtesy of University of Leicester

Scientists investigating a 'biochemical switch' linked to strokes and heart disease claim to have made an advance in understanding how it is 'turned on'.

The work was led by a team at the University of Leicester, working in collaboration with Cardiff University, to investigate the 'biochemical switch' identified as the P2X1 receptor.

Lead researcher Professor Richard Evans, of the University of Leicester Department of Cell Physiology & Pharmacology, said: "P2X1 receptors are protein molecules expressed on blood platelets which are cells involved in blood clotting. Drugs that block these receptors have the potential to reduce "dangerous" blood clotting that leads to strokes and heart attacks.

"Our research has looked at how the P2X1 receptor is "turned on." By biochemical studies and purifying the P2X1 receptor and using an electron microscope we have 'visualised' the receptor and detected changes in its shape when it is activated.

"The P2X1 receptor is made of three identical parts and we have shown that activation leads to these twisting against each-other. We found that if we chemically locked the receptor to stop this twisting, then the P2X1 receptor could not be fully activated.

"This is important as it gives the first realistic insight into how these novel receptors are turned on.

"This work will help to develop drugs that can stop the P2X1 receptor being "turned on" and would be useful to prevent stroke and heart attack."

The breakthrough was published in the Proceedings of the National Academy of Sciences. The research project was undertaken at the University of Leicester in the Department of Cell Physiology & Pharmacology and with Ralf Schmid in the University of Leicester Department of Biochemistry, along with Mark Young at Cardiff University. The study was funded by the Wellcome Trust and the British Heart Foundation.


Story Source:

The above story is based on materials provided by University of Leicester. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. A. Roberts, R. C. Allsopp, S. El Ajouz, C. Vial, R. Schmid, M. T. Young, R. J. Evans. Agonist binding evokes extensive conformational changes in the extracellular domain of the ATP-gated human P2X1 receptor ion channel. Proceedings of the National Academy of Sciences, 2012; DOI: 10.1073/pnas.1201872109

Cite This Page:

University of Leicester. "New insight into how 'chemical switch' that increases risk of stroke and heart disease risk is turned on." ScienceDaily. ScienceDaily, 6 March 2012. <www.sciencedaily.com/releases/2012/03/120306072910.htm>.
University of Leicester. (2012, March 6). New insight into how 'chemical switch' that increases risk of stroke and heart disease risk is turned on. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/03/120306072910.htm
University of Leicester. "New insight into how 'chemical switch' that increases risk of stroke and heart disease risk is turned on." ScienceDaily. www.sciencedaily.com/releases/2012/03/120306072910.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins